Lexaria Bioscience granted two new US patents
Lexaria Bioscience Corp. (OTCQX:LXRP, CSE:LXX), the drug delivery firm, announced Thursday it has been granted two new US patents. The new patents are related to certain cannabinoid infused beverage compositions utilizing Lexaria's proprietary DehydraTECH process which continue to strengthen the company's intellectual property in the cannabis beverage market. Lexaria now has six granted patents in the United States and four granted patents in Australia. Newly granted patent No. 10,103,225 and No. 10,084,044 provide protection for compositions as well as methods for making the compositions, each of which include the use of both non-psychoactive cannabinoids such as CBD and also psychoactive cannabinoids such as THC. The company said it is currently pursuing accelerated examination for patent applications in Australia based on these newest U.S. patents and hopes to receive two corresponding Australian patents granted by the end of 2018. The company said it has more than 50 patent applications filed worldwide across an increasingly diverse range of patent families. Shares of Lexaria were up 4.49% at C$2.28 on Thursday.